Therefore, intracoronary epinephrine was associated with encouraging but exploratory findings, and the higher success rate in primary no-reflow may reflect earlier intervention and less severe microvascular damage. Its modest advantage over adenosine suggests potential therapeutic value, though evidence remains limited and heterogeneous.
SILVA et al. (Mon,) studied this question.